Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D Abstract PURPOSE: MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of MYC-R (single-, double-, and triple-hit statu...
Source: Clinical Lymphoma and Myeloma - September 9, 2019 Category: Cancer & Oncology Authors: Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Tags: J Clin Oncol Source Type: research

Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.
CONCLUSION: CART-related GI-AEs occur in 15% of patients treated with CART. These symptoms are typically mild and self-limiting, requiring only symptomatic treatment. Nevertheless, CART may, in rare cases, lead to refractory colitis. PMID: 31478934 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 30, 2019 Category: Cancer & Oncology Authors: Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y Tags: Am J Clin Oncol Source Type: research

SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Abstract Therapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immunotherapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with the immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T-cell-directed strategies designed to promote cytotoxic activity against myeloma cells, as embodied by chimeric antigen receptor-modified T cells (CAR-T) and bispecific T-cell-engaging agents. Early clinical trial results with these classes of ther...
Source: Clinical Lymphoma and Myeloma - August 7, 2019 Category: Cancer & Oncology Authors: Madduri D, Dhodapkar MV, Lonial S, Jagannath S, Cho HJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation.
Abstract BACKGROUND: Obesity has implications for hematopoietic progenitor cell (HPC) mobilization, chemotherapy administration, and medication dosing. We analyzed the impact of obesity on HPC mobilization as well as key outcomes that are associated with cell dose in autologous hematopoietic cell transplantation (AHCT) recipients. METHODS: We conducted a retrospective cohort study on 556 consecutive eligible AHCT recipients at our institution from 1/2004 to 12/2009. Patients were categorized into four groups based on the body mass index (BMI): underweight (BMI 
Source: Clinical Lymphoma and Myeloma - August 5, 2019 Category: Cancer & Oncology Authors: Khouri J, Rybicki L, Majhail NS, Kalaycio M, Pohlman B, Hill B, Jagadeesh D, Dean R, Hamilton B, Sobecks R, Koo A, Liu H Tags: J Clin Apher Source Type: research

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population. METHODS: A total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis. RESULTS: The pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance ov...
Source: Clinical Lymphoma and Myeloma - July 22, 2019 Category: Cancer & Oncology Authors: Ogasawara K, Newhall K, Maxwell SE, Dell'Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y Tags: Clin Pharmacokinet Source Type: research

Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Abstract The treatment of adult acute lymphoblastic leukemia (ALL) has largely followed the successful pediatric model that uses multi-agent chemotherapy regimens. Although cytotoxic chemotherapy can induce complete remissions, elderly patients are frequently unable to tolerate its intensity owing to toxicities and comorbidities. Elderly patients particularly often relapse, leading to a 5-year overall survival (OS) of only 20%. In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; c...
Source: Clinical Lymphoma and Myeloma - July 3, 2019 Category: Cancer & Oncology Authors: Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies.
This article discusses recent advances in PET quantification that can improve reliability and accuracy of characterizing hematological malignancies." PMID: 31084773 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 16, 2019 Category: Cancer & Oncology Authors: Raynor WY, Zadeh MZ, Kothekar E, Yellanki DP, Alavi A Tags: PET Clin Source Type: research

68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma.
We report a case of plasmacytoma with suspicious renal cell carcinoma, in whom Ga CXCR-4 PET/CT revealed tracer-avid lesion in the left perinephric region. PET/CT-guided biopsy from the tracer-avid lesion revealed plasmacytoma. PET/CT-imaging and guided biopsy using Ga CXCR4 receptor ligand, proved its usefulness for accurate localization of the culprit lesion and helped in definitive management of the patient. PMID: 30985424 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 12, 2019 Category: Cancer & Oncology Authors: Kumar R, Mittal BR, Sood A, Singh H, Shukla J, Nada R, Rathi M Tags: Clin Nucl Med Source Type: research

Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Abstract Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in the allogenic stem cell transplant (allo-SCT) setting. It is possible that the efficacy of mogamulizumab could be established by the occurrence of skin rashe...
Source: Clinical Lymphoma and Myeloma - March 23, 2019 Category: Cancer & Oncology Authors: Ureshino H, Kamachi K, Kimura S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.
Abstract BACKGROUND: With the improvement in the survival of breast cancer, developing second primary malignancy becomes a serious health issue. The aim of this study was to explore the survival of breast cancer patients with second primary malignancy, and to evaluate the impact of chemotherapy on the risk of different cancer sites. METHOD: Obtaining data from the Surveillance, Epidemiology, and End Results database, we calculated the standardized incidence ratio (SIR) for second primary malignancy in breast cancer survivors between 2000 and 2014. Overall survival and cancer-specific survival were analyzed wi...
Source: Clinical Lymphoma and Myeloma - March 19, 2019 Category: Cancer & Oncology Authors: Wei JL, Jiang YZ, Shao ZM Tags: Int J Clin Oncol Source Type: research

Waldenstr öm Macroglobulinemia: Unusual Presentation With Cast Nephropathy/Light Chain Tubulopathy.
We present an interesting case of Cast Nephropathy and light chain tubulopathy in an 81-year-old female patient with Waldenstrom Macroglobulinemia who required medical attention for worsening renal failure. Serum protein electrophoresis/Immunofixation showed IgM Kappa monoclonal gammopathy. Renal biopsy was remarkable for cast nephropathy and light chain tubulopathy. Furthermore on bone marrow biopsy a low grade B cell lymphoproliferative disorder with plasmacytic differentiation was present. This was most consistent with lymphoplasmacytic lymphoma, accounting for 50-60 percent of total bone marrow cellularity, in a hyperc...
Source: Clinical Lymphoma and Myeloma - February 27, 2019 Category: Cancer & Oncology Authors: Ashraf M, Rastogi P Tags: Clin Med Insights Case Rep Source Type: research

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
CONCLUSION: The Sebia FLC assay provides inequivalent absolute results from the Freelite assay. Despite lower absolute FLC values, the kinetics of response and relapse is exactly the same. As with other FLC assays available, follow-up of MM with the same method is advisable. PMID: 30799237 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2019 Category: Cancer & Oncology Authors: Caillon H, Avet-Loiseau H, Attal M, Moreau P, Decaux O, Dejoie T Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
This study aimed to develop a population pharmacokinetic model for lenalidomide in multiple cancers, including CLL, to identify any disease-related differences in disposition. METHODS: Lenalidomide concentrations from four clinical trials were collated (1999 samples, 125 subjects), covering four cancers (multiple myeloma, CLL, acute myeloid leukaemia and acute lymphoblastic leukaemia) and a large dose range (2.5 - 75mg). A population pharmacokinetic model was developed with NONMEM, and patient demographics were tested as covariates. RESULTS: The data were best fitted by a one-compartment kinetic model with absorp...
Source: Clinical Lymphoma and Myeloma - January 22, 2019 Category: Cancer & Oncology Authors: Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR Tags: Br J Clin Pharmacol Source Type: research

Acalabrutinib for adults with mantle cell lymphoma.
Abstract INTRODUCTION: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains the great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. However, ibrutinib-related adverse events due to off-target inhibition of other kinases, led to the development of more selective molecules with comparable efficacy and ...
Source: Clinical Lymphoma and Myeloma - January 14, 2019 Category: Cancer & Oncology Authors: Jurczak W, Długosz-Danecka M, Wang M Tags: Expert Rev Clin Pharmacol Source Type: research

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
CONCLUSION: Binimetinib had tolerable safety profile with a minimal response in RAS-mutant AML. Future studies should focus on better patient selection and synergistic combination therapies involving MEK inhibition. PMID: 30635233 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 20, 2018 Category: Cancer & Oncology Authors: Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
Abstract BACKGROUND: Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML. PATIENTS AND METHODS: We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AM...
Source: Clinical Lymphoma and Myeloma - December 6, 2018 Category: Cancer & Oncology Authors: Ciftciler R, Demiroglu H, Buyukasık Y, Aladag E, Aksu S, Haznedaroglu IC, Sayınalp N, Ozcebe O, Malkan UY, Goker H Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
PMID: 30594446 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Bond DA, Dotson E, Awan FT, Baiocchi RA, Blum KA, Maddocks K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Chronic Neutrophilic Leukemia: Current and Future Perspectives.
Abstract Chronic neutrophilic leukemia (CNL) is a BCR-ABL1-negative myeloproliferative neoplasm with notably dismal survival. The current 2016 World Health Organization classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable myelodysplastic/myeloproliferative neoplasm overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoietic stem-cell transplantation remains the primary therapeutic option for the effe...
Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Venugopal S, Mascarenhas J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
CONCLUSION: There are a number of challenges associated with the use of copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, although they are transient, reversible, and rarely of clinical significance; this report provides guidance as to their management. PMID: 30584024 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
CONCLUSIONS: The five serum markers, LDH, IgM, IgG, IgA, and К, each yielded a specific efficacy in differential diagnosis of WM. The single marker with the highest diagnostic efficiency was the serum IgM level. However, a combination of multiple serum markers was better than the use of a single marker in diagnosing WM. The combined use of all five serum markers provided the most effective diagnosis, with an AUC of .952 and sensitivity and specificity of 87.8% and 86.9%, respectively. PMID: 30485557 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 28, 2018 Category: Cancer & Oncology Authors: Zou H, Yang R, Liao ZX, Qin TD, Chen P, Zhang BY, Cao YP, Huang HF Tags: J Clin Lab Anal Source Type: research

Systemic Capillary Leak Syndrome (Clarkson Syndrome) in Cancer Patients: A Systematic Review.
Abstract Systemic capillary leak syndrome (SCLS) is a rare disease characterized by shock caused by capillary hyperpermeability. The disease can occur in cancer patients and effective therapeutic strategies have not been established yet. The aim of the study was to analyze the clinical and laboratory data, treatment modalities, and mortality rate of patients and to identify contributing factors leading to mortality of SCLS in cancer. We searched MEDLINE (inception to July 2018) and of 4612 articles, we identified 62 case reports on SCLS associated with cancer or cancer-related drugs in a total of 53 articles. SCLS...
Source: Clinical Lymphoma and Myeloma - November 6, 2018 Category: Cancer & Oncology Authors: Shin JI, Lee KH, Lee IR, Oh JH, Kim DW, Shin JW, Eo TS, Kronbichler A, Eisenhut M, van der Vliet HJ Tags: J Clin Med Source Type: research

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.
We present a review of the current literature regarding HS diagnosis, treatment, and outcomes. Additionally, we describe the first reported case of HS transdifferentiated from follicular lymphoma that had a dramatic and durable response to rituximab/bendamustine alone as initial treatment. Unlike traditional chemotherapy regimens, this treatment was well tolerated and had a good toxicity profile. The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are be...
Source: Clinical Lymphoma and Myeloma - October 13, 2018 Category: Cancer & Oncology Authors: Farris M, Hughes RT, Lamar Z, Soike MH, Menke JR, Ohgami RS, Winkfield K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
PMID: 30392824 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 13, 2018 Category: Cancer & Oncology Authors: Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk NWCJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Corrigendum.
Authors: PMID: 30249331 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 26, 2018 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Whole-Body MR Imaging: The Novel, "Intrinsically Hybrid," Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond.
Whole-Body MR Imaging: The Novel, "Intrinsically Hybrid," Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond. PET Clin. 2018 Oct;13(4):505-522 Authors: Lecouvet FE, Van Nieuwenhove S, Jamar F, Lhommel R, Guermazi A, Pasoglou VP Abstract Whole-body MR imaging (WB-MR imaging) has become a modality of choice for detecting bone metastases in multiple cancers, and bone marrow involvement by multiple myeloma or lymphoma. Combination of anatomic and functional sequences imparts an inherently hybrid dimension to this nonirradiating tool and extends the screening of malignancies outside t...
Source: Clinical Lymphoma and Myeloma - September 18, 2018 Category: Cancer & Oncology Authors: Lecouvet FE, Van Nieuwenhove S, Jamar F, Lhommel R, Guermazi A, Pasoglou VP Tags: PET Clin Source Type: research

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization.
Conclusions: Late afternoon administration of plerixafor provides efficient stem cell mobilization. PMID: 30186032 [PubMed] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 8, 2018 Category: Cancer & Oncology Authors: El Rahi C, Cox JE, May R, Carrum G, Anyadike GO, Scholoff A, Kamble R Tags: Clin Med Insights Blood Disord Source Type: research

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
CONCLUSION: The combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL. PMID: 30122201 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 22, 2018 Category: Cancer & Oncology Authors: Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
CONCLUSION: These data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients. PMID: 30122202 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 22, 2018 Category: Cancer & Oncology Authors: Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
This study aimed to evaluate correlates of TKI NA using EM and test the diagnostic accuracy of subjective adherence measures. PATIENTS AND METHODS: CML patients receiving a TKI for any duration were enrolled at 4 hematology institutes, and adherence was measured for 4 months. EM adherence was the reference adherence measure, expressed as the percentage of days with the drug taken as prescribed. Subjective adherence was measured using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) self-report and clinician-reported visual analog scale (VAS) at 2 time points. Baseline theory-derived co...
Source: Clinical Lymphoma and Myeloma - August 22, 2018 Category: Cancer & Oncology Authors: Leader A, Gafter-Gvili A, Benyamini N, Dreyer J, Calvarysky B, Amitai A, Yarchovsky-Dolberg O, Sharf G, Tousset E, Caspi O, Ellis M, Levi I, Raanani P, De Geest S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
Conclusion Prescription drug coverage is associated with decreased use of classic cytotoxic chemotherapy and better survival among Medicare beneficiaries with myeloma, which suggests improved access to all existing treatment options. As oral targeted agents increasingly replace parenteral chemotherapy in oncology, adjustments in coverage policy are needed to ensure access to optimal treatment. PMID: 30113885 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 16, 2018 Category: Cancer & Oncology Authors: Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ Tags: J Clin Oncol Source Type: research

TEMPI Syndrome: Erythrocytosis in Plasma Cell Dyscrasia.
Abstract TEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. The etiology and pathophysiology of this condition remains elusive. Nevertheless, clonal plasma cells and monoclonal protein appear to be major contributors. The early diagnosis of TEMPI syndrome is essential because therapies targeting the underlying plasma cells can lead to a dramatic response. Bortezomib-based chemotherapy, da...
Source: Clinical Lymphoma and Myeloma - August 9, 2018 Category: Cancer & Oncology Authors: Zhang X, Fang M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.
Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Abstract In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which ...
Source: Clinical Lymphoma and Myeloma - August 6, 2018 Category: Cancer & Oncology Authors: Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Tags: Nat Rev Clin Oncol Source Type: research

LAMP1 Overexpression Predicts for Poor Prognosis in Diffuse Large B-cell Lymphoma.
Abstract INTRODUCTION: Lysosomal-associated membrane protein 1 (LAMP1) is a lysosomal and plasma membrane protein that contributes to tumor metastatic potential and differentiation. PATIENTS AND METHODS: We performed immunohistochemical staining to investigate LAMP1 protein expression levels in 122 diffuse large B-cell lymphoma (DLBCL) tumor samples and 45 reactive hyperplasia tissues. Correlations between LAMP1 expression, various clinicopathologic features, and patient prognosis were evaluated by univariate and multivariate analyses. RESULTS: LAMP1 expression was greater in the DLBCL tissues than in th...
Source: Clinical Lymphoma and Myeloma - August 3, 2018 Category: Cancer & Oncology Authors: Dang Q, Zhou H, Qian J, Yang L, Huang J, Zhang Y, Shi W Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Immunophenotypic Profile and Clinical Outcome of Monoclonal B-cell Lymphocytosis in Kidney Transplantation.
In conclusion, our data suggest that MBL is an age-related disorder, with non-CLL MBL being the most common subtype among KT recipients. This article is protected by copyright. All rights reserved. PMID: 30074641 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 3, 2018 Category: Cancer & Oncology Authors: Alfano G, Fontana F, Colaci E, Franceschini E, Ligabue G, Messerotti A, Bettelli F, Grottola A, Gennari W, Potenza L, Guaraldi G, Mussini C, Luppi M, Cappelli G Tags: Clin Transplant Source Type: research

Corrigendum.
Authors: PMID: 30037545 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 25, 2018 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...
Source: Clinical Lymphoma and Myeloma - July 13, 2018 Category: Cancer & Oncology Authors: Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D, Yan F, Nomie K, Romaguera J, Ahmed M, Wang ML Tags: J Exp Clin Cancer Res Source Type: research

Corrigendum.
Authors: PMID: 29958571 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 1, 2018 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
CONCLUSION: Entospletinib monotherapy at 800 mg twice daily demonstrated limited activity in patients with advanced, relapsed DLBCL. PMID: 29934062 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 6, 2018 Category: Cancer & Oncology Authors: Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, Ye W, Shi W, Assouline S, Sharman J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
CONCLUSION: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers. PMID: 29793653 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 29, 2018 Category: Cancer & Oncology Authors: Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cutaneous sarcoidosis: a new subset in the spectrum of paraneoplastic dermatoses.
CONCLUSION: Our results suggest that sarcoidosis is a new subset in the spectrum of paraneoplastic syndrome. We propose that lymphoproliferative disorders should be considered in patients with cutaneous sarcoidosis who have a poor response to conventional therapy or whose skin biopsy shows a significant number of mitoses. PMID: 29779211 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 20, 2018 Category: Cancer & Oncology Authors: El-Khalawany M, Mosbeh A, Aboeldahab S, Ali S Tags: Clin Exp Dermatol Source Type: research

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry.
PMID: 29778693 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 9, 2018 Category: Cancer & Oncology Authors: Gora-Tybor J, Sacha T, Wącław J, Niesiobędzka-Krężel J, Grzybowska-Izydorczyk O, Mędraś E, Dereń-Wagemann I, Patkowska E, Seferyńska I, Lewandowski K, Wache A, Blajer-Olszewska B, Wątek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational  Study.
CONCLUSION: In real life, ponatinib is a "niche-drug" reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates. PMID: 29773429 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2018 Category: Cancer & Oncology Authors: Shacham-Abulafia A, Raanani P, Lavie D, Volchek Y, Ram R, Helman I, Shargian L, Gourevitch A, Chubar E, Ratzon R, Rozovski U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.
Abstract Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in the front-line setting. The long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus, clinical trials require approximately 5 to 8 years from activation to completion and analysis of outcomes. This duration resul...
Source: Clinical Lymphoma and Myeloma - May 5, 2018 Category: Cancer & Oncology Authors: Narkhede MS, Cheson BD Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
las F PMID: 29753690 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Marrero WD, Cruz-Chacón A, Castillo C, Cabanillas F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
We present a retrospective analysis to compare the hematologic and organ response in patients who received bortezomib-based therapy before autologous stem cell transplantation (ASCT) versus those who received non-bortezomib-based therapy before ASCT and those who underwent ASCT at diagnosis. PATIENTS AND METHODS: Of a total of 63 patients who underwent ASCT for light chain amyloidosis, 34 received bortezomib-based therapy before ASCT (Bor-ASCT) and 29 did not receive bortezomib therapy (non-Bor-ASCT). A greater number of patients had involvement of ≥ 3 organs and cardiac involvement in the Bor-ASCT group, sugg...
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States.
Abstract BACKGROUND: Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States. PATIENTS AND METHODS: We performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the subgroups. Multivariate analyses were used to determine the factors affecting survival. RESULTS: For the 797 patients with NK/T-cell lymphoma, nasal type...
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Kommalapati A, Tella SH, Ganti AK, Armitage JO Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy.
PMID: 29752211 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Geller S, Pitter K, Moskowitz A, Horwitz SM, Yahalom J, Myskowski PL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature.
CONCLUSION: The frequency of most chromosomal rearrangements successfully identified in our study and their lineage correlated with those reported in the published data. PMID: 29748040 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 25, 2018 Category: Cancer & Oncology Authors: Chebihi ZT, Belkhayat A, Chadli E, Hilal L, Skhoun H, Hessissen L, El Khorassani M, El Kababri M, Kili A, Khattab M, Bakri Y, Dakka N Tags: Clin Lymphoma Myeloma Leuk Source Type: research

PD-1 Blocks Lytic Granule Polarization with Concomitant Impairment of Integrin 'Outside-in' Signaling in Natural Killer Cell Immunological Synapse.
CONCLUSION: Our results suggest that NK cell cytotoxicity is inhibited by PD-1 engagement, which blocks lytic granule polarization to NK cell immunological synapse with concomitant impairment of integrin 'outside-in' signaling. This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function. PMID: 29679656 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 18, 2018 Category: Cancer & Oncology Authors: Huang Y, Chen Z, Jang JH, Baig MS, Bertolet G, Schroeder C, Huang S, Hu Q, Zhao Y, Lewis DE, Qin L, Zhu MX, Liu D Tags: J Allergy Clin Immunol Source Type: research

La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease.
Abstract It has been long sought to specifically eliminate B-cell clones that generate autoreactive antibodies, while sparing the immune system when combating autoimmune disease. Although it was impossible to achieve this goal before, newly developed techniques have made it feasible today. Autoantibodies against La/SSB were involved in several autoimmune diseases. Here, we aimed to introduce La/SSB epitope-based chimeric autoantibody receptors (CAAR) into NK92MI cells enabled it to destroy the corresponding La/SSB-specific B cell receptor (BCR) -bearing lymphoma cells (LaA-BCR-Romas, LaA-BCR-Maver-1, and LaA-BCR-J...
Source: Clinical Lymphoma and Myeloma - April 16, 2018 Category: Cancer & Oncology Authors: Meng H, Sun X, Song Y, Zou J, An G, Jin Z, Yang L Tags: Clin Immunol Source Type: research